15 November 2017 - - Canadian drug development company Milestone Pharmaceuticals is sponsoring the launch of the PSVT Place Registry , an online portal for patients who have paroxysmal supraventricular tachycardia (PSVT), or suspect they have it, to share experiences managing their condition, the company said.

For the patients living with paroxysmal supraventricular tachycardia, heart rate can unexpectedly spike from a normal 60 to 100 beats per minute to over 200 bpm, causing palpitations, pain and anxiety.

This recurring and sporadic condition is commonly misdiagnosed and not well understood by many.

Milestone said the information from the registry is intended as a resource for participants, their families, their doctors, and the research community to better understand PSVT-related symptoms, diagnosis, patient self-management, medical treatments, and the impact of PSVT on quality of life for patients.

Milestone, headquartered in Montreal, Canada with a US subsidiary in Charlotte, N.C., is a clinical stage drug development company focused on developing etripamil, a calcium channel blocker intended to provide fast-acting and short-acting treatment of PSVT episodes.